It struck at the end of July. A ‘scandal’ in science shook the Republic. Research by the NDR (Norddeutscher Rundfunk), NDR (Westdeutscher Rundfunk) and the Süddeutsche Zeitung revealed that German scientists are involved in a “worldwide scandal”. More that 5000 scientists in German universities, institutes and federal authorities had, with public funds, published their work in on-line pseudoscientific publishing houses that do not comply with the basic rules and for assuring scientific quality. The public and not just a few scientists heard for the first time about “predatory publishing houses” and “predatory journals”.
Predatory publishing houses, whose presentation in phishing mails is quite professional, offer scientists Open Access (OA) publication of their scientific studies at a cost, whereby they imply that their papers will be peer reviewed. No peer review is carried out, and the articles are published on the web site of these “publishing houses”, which however are not listed in the usual search engines such as PubMed. Every scientist in Germany finds several such invitations per day in his or her e-mails. If you are a scientist and receive none, you should be worried about it. Continue reading
Slides of my talk at the FENS Satellite-Event ‘How reproducible are your data?’ at Freie Universität, 6. July 2018, Berlin
- Let’s get this out of the way: Reproducibility is a cornerstone of science: Bacon, Boyle, Popper, Rheinberger
- A ‘lexicon’ of reproducibility: Goodman et al.
- What do we mean by ‘reproducible’? Open Science collaboration, Psychology replication
- Reproducible – non reproducible – A false dichotomy: Sizeless science, almost as bad as ‘significant vs non-significant’
- The emptiness of failed replication? How informative is non-replication?
- Hidden moderators – Contextual sensitivity – Tacit knowledge
- “Standardization fallacy”: Low external validity, poor reproducibility
- The stigma of nonreplication (‘incompetence’)- The stigma of the replicator (‘boring science’).
- How likely is strict replication?
- Non-reproducibility must occur at the scientific frontier: Low base rate (prior probability), low hanging fruit already picked: Many false positives – non-reproducibility
- Confirmation – weeding out the false positives of exploration
- Reward the replicators and the replicated – fund replications. Do not stigmatize non-replication, or the replicators.
- Resolving the tension: The Siamese Twins of discovery & replication
- Conclusion: No scientific progress without nonreproducibility: Essential non-reproducibility vs . detrimental non-reproducibility
- Further reading
Open Science Collaboration, Psychology Replication, Science. 2015 ;349(6251):aac4716
Goodman et al. Sci Transl Med. 2016;8:341ps12.
There is a lot of thinking going on today about how research can be made more efficient, more robust, and more reproducible. At the top of the list are measures for improving internal validity (for example randomizing and blinding, prespecified inclusion and exclusion criteria etc.), measures for increasing sample sizes and thus statistical power, putting an end to the fetishization of the p-value, and open access to original data (open science). Funders and journals are raising the bar for applicants and authors by demanding measures to safeguard the validity of the research submitted to them.
Students and young researchers have taken note, too. I teach, among other things, statistics, good scientific practice and experimental design and am impressed every time by the enthusiasm of the students and young post docs, and how they leap into the adventure of their scientific projects with the unbent will to “do it right”. They soak up suggestions for improving reproducibility and robustness of their research projects like a dry sponge soaks up water. Often however the discussion is in the end not satisfying, especially when we discuss students’ own experiments and approaches to research work. I often hear: “That’s all very good and fine, but it won’t get by with my group leader.” Group leaders would tell them: “That is the way we have always done that, and it got us published in Nature and Science”, “If we do it the way you suggest, it won’t get through the review process”, or “We then could only get it published in PLOS One (or Peer J, F1000 Research etc.) and then the paper will contaminate your CV”, etc.
I often wish that not only the students would be sitting in the seminar room, but also their supervisors with them! Continue reading
I failed to reproduce the results of my experiments! Some of us are haunted by this horror vision. The scientific academies, the journals and in the meantime the sponsors themselves are all calling for reproducibility, replicability and robustness of research. A movement for “reproducible science” has developed. Sponsorship programs for the replication of research papers are now in the works.In some branches of science, especially in psychology, but also in fields like cancer research, results are now being systematically replicated… or not, thus we are now in the throws of a “reproducibility crisis”.
Now Daniel Fanelli, a scientist who up to now could be expected to side with those who support the reproducible science movement, has raised a warning voice. In the prestigious Proceedings of the National Academy of Sciences he asked rhetorically: “Is science really facing a reproducibility crisis, and if so, do we need it?” So todayon the eve, perhaps, of a budding oppositional movement, I want to have a look at some of the objections to the “reproducible science” mantra. Is reproducibility of results really the fundament of scientific methods? Continue reading
It is for good reason that researchers are the object of envy. When not stuck with bothersome tasks such as grant applications, reviews, or preparing lectures, they actually get paid for pursuing their wildest ideas! To boldly go where no human has gone before! We poke about through scientific literature, carry out pilot experiments that surprisingly almost always succeed. Then we do a series of carefully planned and costly experiments. Sometimes they turn out well, often not, but they do lead us into the unknown. This is how ideas become hypotheses; one hypothesis leads to those that follow, and voila, low and behold, we confirm them! In the end, sometimes only after several years and considerable wear and tear on personnel and material, we manage then to weave a “story” out of them (see also). Through a complex chain of results the story closes with a “happy end”, perhaps in the form of a new biological mechanism, but at least as a little piece to fit the puzzle, and it is always presented to the world by means of a publication. Sometimes even in one of the top journals. Continue reading
Tuberculosis kills far more than a million people worldwide per year. The situation is particularly problematic in southern Africa, eastern Europe and Central Asia. There is no truely effective vaccination for tuberculosis (TB). In countries with a high incidence, a live vaccination is carried out with the diluted vaccination strain Bacillus Calmette-Guérin (BCG), but BCG gives very little protection against tuberculosis of the lungs, and in all cases the vaccination is highly variable and unpredictable. For years, a worldwide search has been going on for a better TB vaccination.
Recently, the British Medical Journal has published an investigation in which serious charges have been raised against researchers and their universities: conflicts of interest, animal experiments of questionable quality, selective use of data, deception of grant-givers and ethics commissions, all the way up to endangerment of study participants. There was also a whistle blower… who had to pack his bags. It all happened in Oxford, at one of the most prestigious virological institutes on earth, and the study on humans was carried out on infants of the most destitute layers of the population. Let’s have a closer look at this explosive mix in more detail, for we have much to learn from it about
- the ethical dimension of preclinical research and the dire consequences that low quality in animal experiments and selective reporting can have;
- the important role of systematic reviews of preclinical research, and finally also about
- the selective (or non) availability and scrutiny of preclinical evidence when commissions and authorities decide on clinical studies.
Medicine is full of myths. Sometimes you even get the impression that it is actually based mostly on myths. Many are so plausible that you would have to be a fool to not believe in them. And so today let us take a closer look at the placebo effect. In doing so we will run into a surprisingly little-known phenomenon: regression to mean. This has also implications for experimenters.
Hardly anyone doubts the almost magic effects of the placebo effect, so perhaps it will surprise you to hear that hard evidence for its existence is rather weak — and that there are some important arguments against its efficiency. Cochrane reviews, after all the golden standard for systematic reviews, did not find convincing evidence for its effectivity. They demonstrate that placebos might be effective when it comes to patient reported outcomes, particularly for pain and nausea. But the effects, should there be any at all, are not that impressive. For so-called “observer reported outcomes”, i.e. whenever study doctors did the measuring, no effectiveness was found at all.
Since you probably consider the placebo effect to be one of the fundaments of medicine and me to be a fool, you might just shake your head and push this post aside. Or you allow me to proffer a few arguments as to why the placebo effect is a clearly overrated phenomenon. You would then also learn something about regression to the mean. And this might even be relevant to your own research.